|
gptkbp:instanceOf
|
gptkb:clinical_trial
|
|
gptkbp:allocates
|
randomized
|
|
gptkbp:clinicalTrials.govIdentifier
|
NCT03987919
|
|
gptkbp:comparatorDrug
|
gptkb:semaglutide
|
|
gptkbp:conditionStudied
|
gptkb:type_2_diabetes
|
|
gptkbp:eligibility
|
adults with type 2 diabetes inadequately controlled with metformin
|
|
gptkbp:endPoint
|
change in HbA1c
change in body weight
|
|
gptkbp:fullName
|
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
SURPASS-2
|
|
gptkbp:intervention
|
parallel assignment
|
|
gptkbp:location
|
multinational
|
|
gptkbp:mask
|
open label
|
|
gptkbp:participants
|
1879
|
|
gptkbp:period
|
Phase 3
|
|
gptkbp:primaryCompletionDate
|
2021
|
|
gptkbp:publishedIn
|
NEJM 2021;385:503-515
|
|
gptkbp:result
|
tirzepatide superior to semaglutide for HbA1c and weight reduction
|
|
gptkbp:sponsor
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:startDate
|
2019
|
|
gptkbp:studiedDrug
|
gptkb:tirzepatide
|
|
gptkbp:bfsParent
|
gptkb:tirzepatide
|
|
gptkbp:bfsLayer
|
7
|